NEW YORK, Sept. 23 (GenomeWeb News) - Gene Logic said that it has lowered its revenue guidance for 2003 to a range of $72 million to $76 million, on a pro forma basis.

In late July, Gene Logic had said it was expecting its pro forma revenues for the year to be between $80 million to $84 million.

Gene Logic said that the pro forma results assume that the company's April 1 acquisition of TherImmune took place on January 1. Actual revenues for the year are expected to be in the range of $65 million to $69 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.